Follow
Mathew Martin
Mathew Martin
Cancer Research UK Newcastle Drug Discovery Unit
Verified email at ncl.ac.uk - Homepage
Title
Cited by
Cited by
Year
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 5047, 2020
4302020
Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors
SWJ Ember, JY Zhu, SH Olesen, MP Martin, A Becker, N Berndt, GI Georg, ...
ACS chemical biology 9 (5), 1160-1171, 2014
2382014
Discovery of a potential allosteric ligand binding site in CDK2
S Betzi, R Alam, M Martin, DJ Lubbers, H Han, SR Jakkaraj, GI Georg, ...
ACS chemical biology 6 (5), 492-501, 2011
1862011
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
NR Brown, S Korolchuk, MP Martin, WA Stanley, R Moukhametzianov, ...
Nature communications 6 (1), 1-12, 2015
1822015
Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains
MP Martin, SH Olesen, GI Georg, E Schönbrunn
ACS chemical biology 8 (11), 2360-2365, 2013
1622013
RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer
RA Patel, KD Forinash, R Pireddu, Y Sun, N Sun, MP Martin, ...
Cancer research 72 (19), 5025-5034, 2012
1572012
Identification and Characterization of an Irreversible Inhibitor of CDK2
E Anscombe, E Meschini, R Mora-Vidal, MP Martin, D Staunton, ...
Chemistry & biology 22 (9), 1159-1164, 2015
1092015
Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines
CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ...
Journal of medicinal chemistry 60 (5), 1746-1767, 2017
1002017
Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition
DJ Wood, S Korolchuk, NJ Tatum, LZ Wang, JA Endicott, MEM Noble, ...
Cell chemical biology 26 (1), 121-130. e5, 2019
942019
A novel approach to the discovery of small‐molecule ligands of CDK2
MP Martin, R Alam, S Betzi, DJ Ingles, JY Zhu, E Schönbrunn
Chembiochem 13 (14), 2128-2136, 2012
902012
Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
GGI Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A
J Med Chem, 2013
872013
FragLites—minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation
DJ Wood, JD Lopez-Fernandez, LE Knight, I Al-Khawaldeh, C Gai, S Lin, ...
Journal of Medicinal Chemistry 62 (7), 3741-3752, 2019
772019
Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors
JY Zhu, RA Cuellar, N Berndt, HE Lee, SH Olesen, MP Martin, JT Jensen, ...
Journal of medicinal chemistry 60 (18), 7863-7875, 2017
762017
Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors
HR Lawrence, MP Martin, Y Luo, R Pireddu, H Yang, H Gevariya, ...
Journal of medicinal chemistry 55 (17), 7392-7416, 2012
752012
A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A
MP Martin, JY Zhu, HR Lawrence, R Pireddu, Y Luo, R Alam, S Ozcan, ...
ACS chemical biology 7 (4), 698-706, 2012
672012
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors
R Li, MP Martin, Y Liu, B Wang, RA Patel, JY Zhu, N Sun, R Pireddu, ...
Journal of medicinal chemistry 55 (5), 2474-2478, 2012
612012
Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2)
R Pireddu, KD Forinash, NN Sun, MP Martin, SS Sung, B Alexander, ...
MedChemComm 3 (6), 699-709, 2012
512012
Structure-based discovery of cyclin-dependent protein kinase inhibitors
MP Martin, JA Endicott, MEM Noble
Essays in biochemistry 61 (5), 439-452, 2017
442017
Molecular profiling and combinatorial activity of CCT 068127: a potent CDK 2 and CDK 9 inhibitor
SR Whittaker, C Barlow, MP Martin, C Mancusi, S Wagner, A Self, E Barrie, ...
Molecular Oncology 12 (3), 287-304, 2018
362018
Discovery of diverse small‐molecule inhibitors of mammalian sterile20‐like kinase 3 (MST3)
SH Olesen, JY Zhu, MP Martin, E Schönbrunn
ChemMedChem 11 (11), 1137-1144, 2016
262016
The system can't perform the operation now. Try again later.
Articles 1–20